AstraZeneca (United Kingdom)-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2021

  1. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2018

  1. First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study

    Breast, Vol. 38, pp. 144-149

2017

  1. RE: Final overall survival: Fulvestrant 500mg vs 250mg in the randomized CONFIRM trial

    Journal of the National Cancer Institute

2015

  1. PTEN loss is associated with worse outcome in HER2-Amplified breast cancer patients but is not associated with trastuzumab resistance

    Clinical Cancer Research, Vol. 21, Núm. 9, pp. 2065-2074

2014

  1. Final overall survival: Fulvestrant 500 mg vs 250 mg in the randomized confirm trial

    Journal of the National Cancer Institute, Vol. 106, Núm. 1

2013

  1. Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: Application of new methodology

    Breast Cancer Research and Treatment, Vol. 138, Núm. 1, pp. 149-155